Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07229937
PHASE2

A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia

Sponsor: Shandong Suncadia Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of the study is to explore the reasonable dosage of HRS-1301 in participants with dyslipidemia. The efficacy and safety of HRS-1301 will be evaluated after 12-weeks treatment.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of HRS-1301 in Participants With Dyslipidemia

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

189

Start Date

2025-11-25

Completion Date

2026-08

Last Updated

2025-12-12

Healthy Volunteers

No

Conditions

Interventions

DRUG

HRS-1301

HRS-1301 Dose 1,oral

DRUG

HRS-1301

HRS-1301 Dose 2,oral

DRUG

HRS-1301

HRS-1301 Dose 3,oral

DRUG

HRS-1301

HRS-1301 Dose 4,oral

DRUG

Placebo

Placebo,oral

Locations (1)

The 2nd Affiliated Hospital of Harbin

Harbin, Heilongjiang, China